

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

VOLUNTARY ANNOUNCEMENT
FORCED SALE OF LISTED SECURITIES

This announcement is made by Aceso Life Science Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company would like to announce that Hao Tian Management (Hong Kong) Limited (“**HT Management**”), an indirect wholly-owned subsidiary of the Company, was notified by its securities broker that, an aggregate of 1,385,116,000 shares (the “**Disposed Shares**”) of Hao Tian International Construction Investment Group Limited (Stock Code: 1341) (“**HTICI**”) were forced to be sold by a third party independent lender (the “**Lender**”) exercising its power of sale pursuant to a security document executed by HT Management as security for a loan facility of HK\$150,000,000 (the “**Loan**”) granted by the Lender to the Company after events of default having been declared by the Lender (the “**Forced Sale**”). The Disposed Shares were sold on the market at an average price of HK\$0.37855 per share, generating an aggregate gross proceeds of approximately HK\$524,336,000.

HT Management was informed that the proceeds of the Forced Sale shall be applied in accordance with the terms of the security document for repayment of the outstanding Loan and accrued interest in the sum of approximately HK\$151 million and, after deduction of all the cost, expenses and liabilities incurred by the Lender for the Forced Sale or otherwise, the remaining balance shall be returned by the Lender to HT Management.

After the Forced Sale, the Company's shareholding in HTICI has been decreased from 28.16% to 10.27%.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 14 July 2025

As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou, J. P. (Australia) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.